Nunziz Announces Expansion of HEALEY ALS Trial Regimen I
Key points
- Expansion of Regimen I from 160 to 240 participants
- Enrollment rate exceeds original expectations
- Philanthropic funds offset increased costs
Full summary
Neurizon Therapeutics Limited, a clinical-stage biotech company, announced an expansion of Regimen I in the HEALEY ALS Platform Trial to 240 participants. The expansion is due to the enrollment rate exceeding original expectations and the absence of a concurrent regimen. The increased sample size aims to maintain statistical power and provide a more robust analysis of subgroups and biomarkers. Neurizon expects last participant dosing in Q2 CY2027, with topline results anticipated in early Q3 CY2027. The expansion is expected to have no impact on Neurizon's costs through to topline results, with only a modest increase in the total cost of completing the full trial.
Guidance
Last participant dosing expected in Q2 CY2027, topline results in early Q3 CY2027
Outlook
Neurizon expects the larger, more robust dataset to strengthen partnering and commercial positioning for NUZ-001.
Summary generated by a large language model. Please interpret with care.